Jupiter Life Line Hospitals: Dividend, split, results 2026

Key developments investors are tracking

Jupiter Life Line Hospitals Limited has reported a series of board-level actions and regulatory updates across FY2023-24 to FY2026, spanning dividends, financial-result approvals, leadership changes, and corporate restructuring. The company disclosed that its Board meeting on May 10, 2024 recommended a dividend of 10 percent, which translates to INR 1 per equity share of face value INR 10 for FY2023-24, subject to shareholder approval at the Annual General Meeting (AGM).

More recently, the company has continued to use board meetings to approve quarterly financial results and related compliance reports, while also communicating trading-window closures for designated employees under SEBI rules. Alongside results-related disclosures, Jupiter Life Line Hospitals also recorded a stock split decision and a small acquisition through a subsidiary, both of which are relevant for shareholders following corporate actions.

FY2023-24 dividend recommendation: INR 1 per share

As per the company’s disclosure, the Board of Directors at its meeting held on May 10, 2024 recommended a dividend of 10 percent for FY2023-24. The company clarified this as INR 1 per equity share, where the face value per share was INR 10.

The recommendation was stated to be subject to shareholder approval at the upcoming AGM. This is a standard process in which the board recommends a final dividend, and shareholders approve it through a resolution at the annual meeting before payment.

Board meeting on October 23, 2026: Q2 and H1 results on agenda

Jupiter Life Line Hospitals Ltd announced that its Board of Directors would convene on October 23, 2026. The key agenda item is to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026, on both standalone and consolidated bases.

The company also indicated that a Limited Review Report would be presented along with the results. In addition, it confirmed that the trading window for designated employees would remain closed until 48 hours after the declaration of these financial results, citing SEBI regulations. Such trading-window restrictions are commonly communicated around results to manage insider-information risk.

Outcome of the July 31, 2026 board meeting

The company also disclosed the outcome of its Board meeting held on July 31, 2026. During that meeting, the board considered and approved the unaudited financial results for the quarter ended June 30, 2026, on both standalone and consolidated bases, along with the limited review report.

Beyond the quarterly approval, Jupiter Life Line Hospitals also announced a leadership change. The board appointed Mr. Harshad Purani as Chief Financial Officer and Key Managerial Personnel (KMP), effective July 31, 2026. For investors, CFO appointments are material because the role oversees financial reporting, internal controls, and investor communication.

Step-down acquisition: Sulcus becomes wholly-owned

In the same July 31, 2026 board outcome, Jupiter Life Line Hospitals stated that its subsidiary, Jupiter Hospital Pharmacy Private Limited (JHPPL), acquired 100 percent of Sulcus Private Limited for INR 3.78 crore. The filing noted that this transaction resulted in Sulcus becoming a wholly-owned step-down subsidiary.

While the disclosure does not provide operational details of Sulcus, the structure is clear: ownership sits with JHPPL, and the entity is classified as a step-down subsidiary from the listed parent.

FY26 performance snapshot and interim dividend

Jupiter Life Line Hospitals announced its Q4 and FY26 results, reporting a consolidated net profit of INR 50.27 crore for the quarter and INR 194.19 crore for the full year. Alongside results, the board declared an interim dividend of INR 1 per share, with a record date of May 22, 2026.

The company stated that the dividend would be paid on or before June 13, 2026. It also clarified that the interim dividend was INR 1 per equity share of face value INR 10 for FY26, as approved at the May 15, 2026 board meeting.

Stock split approved: INR 10 face value into INR 2

At the May 15, 2026 board meeting, Jupiter Life Line Hospitals also approved the sub-division of each existing equity share of face value INR 10 into five equity shares of face value INR 2 each. The company said the move is intended to enhance liquidity and make shares more affordable.

To implement this, the board also approved the alteration of the capital clause of the Memorandum of Association to give effect to the split. These are procedural steps typically required for corporate actions that change share capital structure.

AGM updates: share split approved, chairman appointment

The company disclosed that its 24th Annual General Meeting was held on July 17, 2026, and that it approved the sub-division of equity shares. It also noted the appointment of Dr. Ajay Thakker as Chairman and Whole Time Director.

The AGM was conducted via video conferencing, and 85.95 percent of outstanding shares were polled. The company stated that all resolutions were passed with the requisite majority. It also specified that alteration of the Articles of Association was approved as a Special Resolution, while the share split and alteration of the capital clause were approved as Ordinary Resolutions.

Corporate action and meeting timeline

The company’s disclosed calendar includes board meetings for quarterly results and the AGM schedule.

What the disclosures mean for compliance and investors

Across these updates, two recurring themes stand out: results-driven board meetings and related compliance controls. The October 23, 2026 meeting is explicitly tied to approving unaudited results and the limited review report for the quarter and half-year ended September 30, 2026. The company’s confirmation of the trading-window closure until 48 hours after results aligns with standard SEBI-compliance practices.

Separately, the combination of dividend decisions and the stock split indicate that the company has used FY26 board meetings for shareholder-facing actions. The interim dividend of INR 1 per share had a clear record date (May 22, 2026) and a payment timeline (on or before June 13, 2026), while the split converted INR 10 face value shares into five INR 2 shares, later approved by shareholders at the AGM.

Key facts at a glance

What to watch next

The company also indicated that its next board meeting for results is scheduled for November 3, 2026, according to its BSE filing. For investors, the next immediate milestone remains the October 23, 2026 results approval for the quarter and half-year ended September 30, 2026, including the limited review report.

With recent actions covering dividends, a stock split, a CFO appointment, and a step-down acquisition, the next set of unaudited numbers and accompanying limited review report will be a key scheduled disclosure as per the company’s stated agenda.